Compare Repligen Corporation Common Stock (RGEN) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Symbotic Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Symbotic Inc trades at $37.62 (market cap $5.31B). The key difference: Repligen Corporation Common Stock is far larger — about 2.1× Symbotic Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Symbotic Inc for 24 Days on average.
| RGEN | SYM | |
|---|---|---|
Market Cap | $11.14B | $5.31B |
Volume | 1,259,263 | 1,244,339 |
Sector | Health | Industrials |
52-Week High | $194.57 | $87.30 |
52-Week Low | $102.87 | $37.90 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $11.02B | $3.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SYM trades at $40.89, down 32% year-to-date and near 52-week lows, with bearish technical signals dominating. Fundamentally, the company shows mixed results with a $22.5 billion backlog and 20%+ revenue growth but negative EBITDA of -$48M and net loss of -$17M in 2025. Recent earnings misses and high customer concentration (85% revenue from Walmart) create uncertainty despite analyst optimism.
The stock presents a high-risk opportunity with significant upside potential if execution improves. Analyst consensus targets $60.33 (47% upside) but near-term risks include continued earnings misses, customer concentration, and weak technical momentum. The 2027 inflection point for new system deployments represents the key growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
